Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001768053 | SCV002008419 | uncertain significance | not provided | 2021-09-17 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect |
Fulgent Genetics, |
RCV005038306 | SCV005665438 | uncertain significance | Acrocephalosyndactyly type I; Beare-Stevenson cutis gyrata syndrome; Jackson-Weiss syndrome; Pfeiffer syndrome; Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis; Crouzon syndrome; Saethre-Chotzen syndrome; Familial scaphocephaly syndrome, McGillivray type; Bent bone dysplasia syndrome 1; Gastric cancer; LADD syndrome 1 | 2024-04-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005330906 | SCV006006161 | uncertain significance | Inborn genetic diseases | 2024-12-23 | criteria provided, single submitter | clinical testing | The c.67C>A (p.P23T) alteration is located in exon 2 (coding exon 1) of the FGFR2 gene. This alteration results from a C to A substitution at nucleotide position 67, causing the proline (P) at amino acid position 23 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |